EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proteomic Changes Induced by the Immunosuppressant Everolimus in Human Podocytes

Maurizio Bruschi iD, Simona Granata, Giovanni Candiano, Andrea Petretto iD, Martina Bartolucci iD, Xhuliana Kajana iD, Sonia Spinelli iD, Alberto Verlato iD, Michele Provenzano, Gianluigi Zaza iD

International Journal of Molecular Sciences · 04.07.2024 · 25 (13) · 7336

DOI: 10.3390/ijms25137336 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.07.2024. Verfasst von Maurizio Bruschi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Nephrology, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy. Hauptthemen laut MEDLINE: Podocytes, Everolimus, Proteomics, Immunosuppressive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS, European Union-Next Generation EU-NRRP M6C2-Investment 2.1 Enhancement and strengthening of biomedical research in the NHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mTOR inhibitors (mTOR-Is) may induce proteinuria in kidney transplant recipients through podocyte damage. However, the mechanism has only been partially defined. Total cell lysates and supernatants of immortalized human podocytes treated with different doses of everolimus (EVE) (10, 100, 200, and 500 nM) for 24 h were subjected to mass spectrometry-based proteomics. Support vector machine and partial least squares discriminant analysis were used for data analysis. The results were validated in urine samples from 28 kidney transplant recipients receiving EVE as part of their immunosuppressive therapy. We identified more than 7000 differentially expressed proteins involved in several pathways, including kinases, cell cycle regulation, epithelial–mesenchymal transition, and protein synthesis, according to gene ontology. Among these, after statistical analysis, 65 showed an expression level significantly and directly correlated with EVE dosage. Polo-Like Kinase 1 (PLK1) content was increased, whereas osteopontin (SPP1) content was reduced in podocytes and supernatants in a dose-dependent manner and significantly correlated with EVE dose (p < 0.0001, FDR < 5%). Similar results were obtained in the urine of kidney transplant patients. This study analyzed the impact of different doses of mTOR-Is on podocytes, helping to understand not only the biological basis of their therapeutic effects but also the possible mechanisms underlying proteinuria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PodocytesEverolimusProteomicsImmunosuppressive AgentsHumansKidney TransplantationPolo-Like Kinase 1ProteomeProtein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene ProteinsFemaleProteinuriaMaleOsteopontin

Stichwörter der Autor:innen

everolimuskidney transplantationmTOR-inhibitorspodocytesproteomics

Substanzen

EverolimusImmunosuppressive AgentsPolo-Like Kinase 1ProteomeProtein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene ProteinsSPP1 protein, humanOsteopontin

Autor:innen und Institutionen

  • Laboratory of Molecular Nephrology, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
  • Department of Experimental Medicine (DIMES), University of Genoa, 16132 Genoa, Italy.
  • Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
  • Proteomics and Clinical Metabolomics Unit at the Core Facilities, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
  • Renal Unit, Department of Medicine, University Hospital of Verona, 37124 Verona, Italy.
  • Nephrology, Dialysis and Transplantation Unit, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.

ORCID-Profile: Maurizio Bruschi, Andrea Petretto, Martina Bartolucci, Xhuliana Kajana, Sonia Spinelli, Alberto Verlato, Gianluigi Zaza

Förderung

  • European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS
  • European Union-Next Generation EU-NRRP M6C2-Investment 2.1 Enhancement and strengthening of biomedical research in the NHS

Zitieren

APA

Bruschi, M., Granata, S., Candiano, G., Petretto, A., Bartolucci, M., Kajana, X., Spinelli, S., Verlato, A., Provenzano, M., & Zaza, G. (2024). Proteomic Changes Induced by the Immunosuppressant Everolimus in Human Podocytes. International Journal of Molecular Sciences, 25(13), 7336. https://doi.org/10.3390/ijms25137336

Vancouver

Bruschi M, Granata S, Candiano G, Petretto A, Bartolucci M, Kajana X, et al. Proteomic Changes Induced by the Immunosuppressant Everolimus in Human Podocytes. International Journal of Molecular Sciences. 2024;25(13):7336. doi:10.3390/ijms25137336

BibTeX
@article{Bruschi2024,
  author = {Bruschi, Maurizio and Granata, Simona and Candiano, Giovanni and Petretto, Andrea and Bartolucci, Martina and Kajana, Xhuliana and Spinelli, Sonia and Verlato, Alberto and Provenzano, Michele and Zaza, Gianluigi},
  title = {Proteomic Changes Induced by the Immunosuppressant Everolimus in Human Podocytes},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {13},
  pages = {7336},
  doi = {10.3390/ijms25137336}
}
Kostenlos starten →